CAMEL Group receives third concurrent NIH R01 grant

June 27, 2015

The National Institute for Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH) has recently awarded a R01 grant to Dr. Marty Pagel and the CAMEL group.  This grant will support a clinical trial that will translate the acidoCEST MRI method to the radiology clinic, which will be used to measure tumor acidosis in patients with breast cancer.  Drs. Pavani Chalasani, Phil Kuo, Amanda Baker, Julio Cárdenas Rodríguez, and Ed Randtke are collaborating with Dr. Pagel and other CAMELs to perform this clinical translational study.

The CAMEL group now has three concurrent NIH R01 grants that support ongoing research with pre-clinical and clinical MRI studies.  CAMEL is only one of three groups on campus at this time that has more than two concurrent R01s.  The group has reached the $1M annual limit in NIH awards, so that future NIH grants will be obtained through multidisciplinary partnerships that can share the award credit.